Legal & General Group Plc Takes Position in CeriBell (NASDAQ:CBLL)

Legal & General Group Plc bought a new stake in CeriBell (NASDAQ:CBLL) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 1,247 shares of the company’s stock, valued at approximately $32,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Rhumbline Advisers purchased a new position in shares of CeriBell during the fourth quarter worth about $320,000. Bank of New York Mellon Corp purchased a new position in CeriBell during the 4th quarter worth approximately $628,000. Charles Schwab Investment Management Inc. acquired a new position in CeriBell during the fourth quarter worth approximately $2,500,000. PNC Financial Services Group Inc. purchased a new stake in CeriBell in the fourth quarter valued at approximately $47,000. Finally, Vanguard Group Inc. acquired a new stake in shares of CeriBell in the fourth quarter valued at approximately $18,015,000.

Insiders Place Their Bets

In other news, CEO Xingjuan Chao sold 3,372 shares of the stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $15.03, for a total value of $50,681.16. Following the completion of the transaction, the chief executive officer now owns 743,079 shares in the company, valued at $11,168,477.37. This trade represents a 0.45 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last ninety days, insiders have sold 24,700 shares of company stock worth $372,434.

CeriBell Trading Up 1.2 %

Shares of NASDAQ:CBLL opened at $16.28 on Friday. CeriBell has a fifty-two week low of $10.01 and a fifty-two week high of $32.75. The company has a 50-day moving average price of $19.03.

CeriBell (NASDAQ:CBLL) last released its earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.08). The business had revenue of $18.53 million during the quarter, compared to the consensus estimate of $17.55 million. On average, equities analysts predict that CeriBell will post -2.46 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on CBLL shares. Canaccord Genuity Group reiterated a “buy” rating and issued a $33.00 price target on shares of CeriBell in a research report on Wednesday, February 26th. LADENBURG THALM/SH SH started coverage on shares of CeriBell in a research note on Friday, April 4th. They set a “buy” rating and a $32.00 target price for the company. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $32.50.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.